Multiple sclerosis and concomitant rheumatologic diseases: prevalence and management.

Authors

Selime Ermurat, Meral Seferoğlu, Ali Özhan Sıvacı

Published in

Multiple sclerosis and related disorders. Volume 116. Pages 108030. Oct 26, 2026. Epub Oct 26, 2026.

Abstract

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system that shares several immunological and genetic pathways with systemic autoimmune disorders. The clinical significance of rheumatologic autoantibody positivity and its impact on treatment decisions in MS remains unclear.
This study aimed to determine the prevalence of rheumatologic autoantibody positivity and confirmed rheumatologic diseases in MS patients, evaluate the progression from isolated autoantibody positivity to clinically defined rheumatologic disease, and compare treatment patterns between patients with MS and concomitant rheumatologic disease (MS-Plus) and those with isolated MS.
In this hybrid retrospective-prospective study, patients diagnosed with MS according to the 2017 McDonald criteria and followed at a tertiary MS center between October 2021 and August 2026 were evaluated. Demographic, clinical, and laboratory data, including rheumatologic autoantibody profiles, were collected. Patients were categorized as MS-Plus, isolated MS, or asymptomatic autoantibody-positive. Disease-modifying therapies (DMTs) were classified according to efficacy level.
Among 588 MS patients, 54 (9.2%) had concomitant rheumatologic disease, most commonly Sjögren syndrome (25.9%). ANA positivity was the most frequently detected autoantibody (9.1%). Only three patients with isolated autoantibody positivity developed a rheumatologic disease during follow-up. High-efficacy DMT use was significantly lower in MS-Plus patients compared with isolated MS (22.2%vs. 42.3%, p = 0.005).
Rheumatologic comorbidity is not uncommon in MS and may influence therapeutic decision-making. Although autoantibody positivity is relatively frequent, progression to overt rheumatologic disease appears rare.

PMID:
42966338
Bibliographic data and abstract were imported from PubMed on 01 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.